lpa

LPA1 receptor antagonist 1(LPA1 R antagonist 1) is a selective and potent lysophosphatidic acid (LPA1) receptor antagonist (IC50 : 25 nM) for the study of idiopathic pulmonary fibrosis.

LPA2 antagonist 2 is a selective and potent LPA2 antagonist (IC50: 28.3 nM) with potential anticancer activity, inhibits LPA3, and can be used in the study of cancer.

LPA2 antagonist 1 is a highly efficient LPA2 antagonist.

16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a type of palmitoyl cyclic lysophosphatidic acid.

Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.

CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.

Z-HA155 (CS-963) selectively and potently inhibits autotaxin with an IC50 of 5.7 nM.

Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.

1-Oleoyl lysophosphatidic acid sodium (1-Oleoyl lysophosphatidic acid sodium salt) salt is an Endogenous agonist of LPA1 and LPA2

Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.

DBIBB is a non-lipid agonist of specific lysophosphatidic acid (LPA2) type 2 G-protein-coupled receptor. It is a potentially active molecule for the treatment of acute radiation syndrome caused by high intensity gamma rays on hematopoietic and gastrointestinal systems. It is an intermediate in organic synthesis and drug research. DBIBB can be used to prepare various compounds that reduce gastrointestinal radiation syndrome, increase intestinal crypt survival and intestinal cell proliferation, and reduce cell apoptosis.

UCM-05194 is a selective LPA1 receptor agonist that can improve neuropathic pain and can be used in the study of progressive system diseases.

AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 μM for recombinant human LPA1 and 0.73 μM for recombinant mouse LPA1.

ASP6432 is an antagonist of type 1 lysophosphatidic acid receptor (LPA1). For human LPA1 and rat LPA1, the IC50s are 11 nM and 30 nM , respectively.

LX-1031 is an effective inhibitor of tryptophan 5-hydroxylase. LX-1031 decreases serotonin (5-HT) synthesis peripherally.

AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic lysophosphatidic acid used in lipid vesicle (liposome) formation.

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid that contains arachidonic acid at the sn-1 position, serving as a precursor to 1-Monoarachidin. It binds with the LPA2/EDG4 receptor and can inhibit the secretion of TNF-α and IL-6 induced by LPS in wild-type dendritic cells but does not affect Lpa2-/- dendritic cells. Additionally, it reduces the differentiation of HT-29 human colon cancer cells into goblet cells in the presence of sodium butyrate.

1-Hexadecyl lysophosphatidic acid (1-Hexadecyl LPA) sodium is an ether analogue of lysophosphatidic acid (LPA) and acts as an LPA receptor agonist.

1-Myristyl-2-hydroxy-sn-glycero-3-PA (1-Myristyl LPA) is a derivative of lysophosphatidic acid. In HEL cells, 1-Myristyl-2-hydroxy-sn-glycero-3-PA can elevate intracellular calcium levels.

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) [1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)] is a phospholipid containing arachidonic acid at the sn-1 position. It binds to the LPA2/EDG4 receptor with an EC50 of 10 nM and is present in the rat brain, representing 37% of arachidonic acid lysophosphatidic acid species. This compound serves as a precursor to 1-arachidonoyl-sn-glycerol and inhibits the secretion of TNF-α and IL-6 from dendritic cells stimulated by wild-type LPS. Additionally, 1-arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can suppress the differentiation of HT-29 colon cancer cells into goblet cells in the presence of sodium butyrate.

GRI977143 is a selective and non-lipid agonist of LPA2 (EC50 = 3.3 μM). GRI977143 inhibits the activation of caspases 3, 7, 8, and 9 and and reduces DNA fragmentation.

1-Oleoyl Lysophosphatidic Acid (1-Oleoyl LPA) is a biologically active phospholipid that can exert multiple biological effects in various disease states of the kidney by activating a complex network of at least six homologous G protein-coupled receptors and their heterotrimeric G proteins. 1-Oleoyl Lysophosphatidic Acid promotes polarization of BV-2 and primary murine microglia toward an M1-like phenotype and can be used to study cancer and atherosclerosis.

BMS-986278 is an orally active and potent hemophosphatidic acid receptor 1 (LPA1) antagonist with Kb values of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively.BMS-986278 may be investigated for use in idiopathic pulmonary fibrosis.